[Skip to Content]
[Skip to Content Landing]
Views 2,631
Citations 0
News From the Food and Drug Administration
November 21, 2017

Relief for Central Sleep Apnea

JAMA. 2017;318(19):1858. doi:10.1001/jama.2017.17118

The FDA has approved an implantable device to help patients with moderate to severe central sleep apnea breathe normally while they slumber.

Marketed as the Remedē System, the device consists of a neurostimulator similar to a cardiac pacemaker. Its transvenous lead and sensing wires are placed in the upper chest to stimulate the phrenic nerve and restore diaphragm contractions to support normal breathing during sleep. The system operates automatically but a physician can noninvasively change its settings through a portable tablet programmer.

First Page Preview View Large
First page PDF preview
First page PDF preview